Coronavirus information from UCLA and UCLA Health
The CNSI will re-open on June 12 for projects with approved Research Ramp-Up Plans.

Magnify

The Next Generation Incubator

Based on technology discovered at UCLA, InvVax is a patented and novel approach to vaccines that will prevent pandemics. Unfortunately, the seasonal flu vaccine is only 60% effective, allowing the influenza virus to take a staggering human toll every year worldwide, in both developed and developing countries alike. InvVax is commercializing the world's first universal influenza vaccine. InvVax mapped the entire flu genome, and used that map to identify the 15 regions of the virus that cannot mutate without it self-destructing. InvVax’s key differentiator is that their vaccine targets only invariant positions.

Graduated in 2017
Location: Pasadena, CA

Contact:
http://inv-vax.com/contact.php